Skip to content

Trial Summary

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse.

Acronym:

CYCLONE 3

ACTRN/NCT /ethics:

NCT05288166

Scientific title:

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Sponsor / Cooperative group:

Eli Lilly and Company

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexMale
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-04-01
Anticipated End Date2027-10-01

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Francis Parnis
Recruitment StatusNot Yet Recruiting